F-18 FDG PET/CT in the evaluation of Takayasu arteritis: An experience from the tropics

Journal of Nuclear Cardiology

Volumn 21, Issue 5, 2014, Pages 993-1000

  Santhosh, Sampath ^a   Mittal, Bhagwant Rai ^a   Gayana, Shankaramurthy ^a   Bhattacharya, Anish ^a   Sharma, Aman ^a   Jain, Sanjay ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

FDG; immunosupression; PET CT; Takayasu arteritis; vasculitis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AORTA ARCH SYNDROME; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; HUMAN; INDIA; MALE; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TROPIC CLIMATE;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INDIA; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAKAYASU ARTERITIS; TOMOGRAPHY, X-RAY COMPUTED; TROPICAL CLIMATE;

EID: 84929939956     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-014-9910-8     Document Type: Article

References (23)

1. Langford CA, Fauci AS. The vasculitis syndromes. In: Fauci Longo, Hauser Kasper, Loscalzo Jameson, editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw Hill; 2012. p. 2116.
2. Hacker M. Monitoring anti-inflammatory therapies in patients with atherosclerosis: FDG PET emerges as the method of choice. Eur J Nucl Med Mol Imaging 2012;39:396-8.
3. Wu YW, Kao HL, Huang CL, Chen MF, Lin LY, Wang YC et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging 2012;39:399-407.
4. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworth SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-34.
5. Bleeker-Rovers CP, Bredie SJ, van der Meer JW, Corstens FH, Oyen WJ. F-18-fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med 2003;61:323-9.
6. Walter MA, Melzer RA, Schindler C, Müller-Brand J, Tyndall A, Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005;32:674-81.
7. Lee SG, Ryu JS, Kim HO, Oh JS, Kim YG, Lee CK, et al. Evaluation of disease activity using F-18 FDG PET-CT in patients with Takayasu arteritis. Clin Nucl Med 2009;34:749-52.
8. Kobayashi Y, Ishii K, Oda K, Nariai T, Tanaka Y, Ishiwata K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med 2005;46:917-22.
9. Webb M, Chambers A, AL-Nahhas A, Mason JC, Maudlin L, Rahman L, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 2004;31:627-34.
10. Arnaud L, Haroche J, Malek Z, Archambaud F, Gambotti L, Grimon G, et al. Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum 2009;60:1193-200.
11. Meller J, Strutz F, Siefker U, Scheel A, Sahlmann CO, Lehmann K, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003;30:730-6.
12. Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G, et al. Takayasu’s arteritis: A study of 104 Italian patients. Arthritis Rheum 2005;53:100-7.
13. Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE. Takayasu’s arteritis. Clinical study of 107 cases. Am Heart J 1977;93:94-103.
14. Park YB, Hong SK, Choi KJ, Sohn DW, Oh BH, Lee MM, et al. Takayasu arteritis in Korea: Clinical and angiographic features. Heart Vessels suppl 1992;7:55-9.
15. Sharma BK, Sagar S, Singh AP, Suri S. Takayasu arteritis in India. Heart Vessels 1992;7:37-43.
16. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56:1000-9.
17. Zheng D, Fan D, Liu L. Takayasu arteritis in China: A report of 530 cases. Heart Vessels 1992;7:32-6.
18. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med 1994;120:919-29.
19. Fuchs M, Briel M, Daikeler T, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012;39:344-53.
20. Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: A review. J Clin Pathol 2002;55:481-6.
21. Dhawan V, Mahajan N, Jain S. Role of C-C chemokines in Takayasu’s arteritis disease. Int J Cardiol 2006;112:105-11.
22. Mahajan N, Dhawan V, Malik S, Jain S. Implication of oxidative stress and its correlation with activity of matrix metalloproteinases in patients with Takayasu’s arteritis disease. Int J Cardiol 2010;145:286-8.
23. Mahajan N, Dhawan V, Malik S, Jain S. Serum levels of soluble receptor for advanced glycation end products (sRAGE) in Takayasu’s arteritis. Int J Cardiol 2010;3:589-91.